



PHARMACEUTICALS EXPORT PROMOTION COUNCIL

(Set up by Ministry of Commerce, Govt. of India)

COPY

Date : 24-05-2010

News / Story reproduced with thanks:- [Pharmaceutical Business review](#)

Health Canada Gives Marketing Approval to Ranbaxy RAN- Atorvastatin Tablets

Published: 24-May-2010

Direct link to the News/Story:-

http://regulatoryaffairs.pharmaceutical-business-review.com/news/health_canada_gives_marketing_approval_to_ranbaxy_ran_atorvastatin_tablets_100524/

Ranbaxy Pharmaceuticals Canada, a wholly owned subsidiary of Ranbaxy Laboratories, has gained approval from Health Canada to market RAN- Atorvastatin tablets (atorvastatin calcium) of strengths 10mg, 20mg, 40mg and 80mg. Ranbaxy Pharmaceuticals Canada said that RAN-Atorvastatin is expected to be made available to all Canadian patients under the Ranbaxy label, subject to provincial formulary listings. Atorvastatin is an oral drug used for lowering blood cholesterol. It also stabilises plaque and prevents strokes through anti-inflammatory and other mechanisms.

Paul Drake, president of Ranbaxy Pharmaceuticals Canada, said: “As a result of our settlement, Ranbaxy is pleased to announce the immediate launch of RAN-Atorvastatin. Atorvastatin is a lipid metabolism regulator marketed under the Lipitor brand.”

Based in Mississauga, Ontario, Ranbaxy Pharmaceuticals Canada is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.